← All stories
Markets
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
Covered by 1 outlet
All coverage · 1 article